Idera Pharmaceuticals, Inc. (IDRA) Stock Ratings

View Stock Quote:

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:

Not Rated

No Current Ratings
View All-Time Ratings

Do the wall street analysts agree?

Consensus Recommendation:

View detailed analyst research

Other Member Ratings

View Most Rated Stocks

Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
jsreich jsreich 12/15/2015 3 months $3.40 $1.83 -46.18% 46 Ended
Comments: Low volume. Limited/vague guidance going forward.
Bandolero Bandolero 12/15/2015 3 months $3.40 $1.83 -46.18% 46 Ended
Comments: resistence has not been passed
jacklantier jacklantier 06/26/2015 3 months $3.56 $3.84 +7.87% 7 Ended
Comments: At a low and will come back up and meet its expected yearly projections.
LyubomirZhelyazkov LyubomirZhelyazkov 05/06/2015 3 months $2.73 $3.51 +28.57% 28 Ended
Comments: Upcoming product launch will be successful
Biotech_Invest Biotech_Invest 12/04/2014 1 Year $4.18 $3.66 -12.46% 12 Ended
Comments: I'm skeptical about IDRA science and particularly about claimed potential of TLR antagonists
Netteligent Netteligent 10/16/2014 3 months $2.20 $5.14 +133.64% 133 Ended
jrdelane jrdelane 06/27/2014 1 Year $3.05 $3.56 +16.72% 16 Ended
Comments: They have great science, trial results will be good
Investing MY way Investing MY way 05/07/2014 1 Year $2.49 $2.81 +12.85% 12 Ended
Comments: Great Management Team and Institutional support for the long term
deitenbeck deitenbeck 03/27/2014 3 months $3.89 $3.02 -22.37% -22 Ended
HarleyDavidson HarleyDavidson 12/31/2013 3 months $4.63 $4.57 -1.3% -1 Ended
Comments: Industry sector growing or poised for growth
B1capital B1capital 11/11/2013 3 months $1.80 $5.14 +185.57% 185 Ended

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ OMX. Investors should undertake their own due diligence and carefully evaluate companies before investing.